| Business Summary | | IGENE
Biotechnology,
Inc.
is
engaged
in
the
business
of
developing,
marketing
and
manufacturing
industrial
microbiology
and
related
biotechnology
products.
AstaXin
is
IGENE's
tradename
for
its
dried
yeast
product
made
from
a
proprietary
strain
of
yeast
developed
by
the
Company.
AstaXin
is
a
natural
source
of
astaxanthin,
a
pigment
that
imparts
the
characteristic
red
color
to
the
flesh
of
salmon,
trout,
prawns
and
certain
other
types
of
fish
and
shellfish.
During
2000,
IGENE
began
investigating
other
possible
commercial
uses
of
astaxanthin,
including
its
application
as
a
human
nutritional
supplement.
The
Company
has
formulated
natural
astaxanthin
as
a
super-antioxidant,
AstaBioCare,
for
the
North
American
dietary
supplement
market. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IGENE
Biotechnology,
Inc.
develops,
manufactures
and
markets
biochemical
products,
derived
from
renewable
agricultural
residues
and
wastes.
For
the
three
months
ended
3/31/01,
sales
totaled
$445
thousand,
up
from
$79
thousand.
Net
loss
increased
17%
to
$526
thousand.
Revenues
reflect
the
commencement
of
large-scale
commercial
trials
of
AstaXin(R).
Net
loss
was
partially
offset
by
increased
marketing
expenses
due
to
the
delivery
of
AstaXin(R)
for
free
or
at
reduced
prices. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Michael Kimelman, 62 | Chairman | Stephen Hiu, Ph.D., 44 | Pres,
Treasurer, Director of R&D | Thomas Kempner, 73 | Vice
Chairman | Patrick Monahan, 50 | Sec.
and Director of Manufacturing |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|